AURAPEP. INDEPENDENTLY VERIFIED. RESEARCH-GRADE QUALITY.
AURAPEP. INDEPENDENTLY VERIFIED. RESEARCH-GRADE QUALITY.
Retatrutide · 10MG
Lyophilized research-grade Retatrutide (LY3437943). A synthetic 39-amino-acid peptide with a C20 fatty diacid modification, originally developed by Eli Lilly and Company and currently in Phase 3 clinical trials. Third-party verified at ≥99% HPLC purity. Single-batch traceable from synthesis to delivery.
ISO 9001 source facility. Cold-chain shipped. Batch-matched COA included with every order.
COMPOUND DETAILS
| Molecular formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular weight | 4731.33 Da |
| Sequence | 39-amino-acid peptide ... |
| CAS number | 2381089-83-2 |
| PubChem CID | - |
EVERY ORDER INCLUDES: PEPTIDE VIAL + PRINTED COA + COLD-PACK INSERT + TRACKED SHIPPING
DUTIES AND TAXES INCLUDED
Every lot is analyzed by an independent third-party laboratory before release. Each batch-matched Certificate of Analysis (COA) documents:
- HPLC purity: Reverse-phase high-performance liquid chromatography confirms purity at ≥99%. A representative chromatogram is included on each COA.
- Mass spectrometry: ESI-MS confirms molecular identity against the expected molecular weight of 4731.33 Da.
- Sequence verification: The 39-amino-acid sequence, including non-coded residues (Aib2, Aib20, α-methyl-Leu13) and the C20 fatty diacid modification at Lys20, is confirmed against the published reference sequence.
- Appearance: White lyophilized powder, free of visible particulates.
- Water content: Karl Fischer titration, reported per lot.
- Endotoxin level: LAL assay, reported per lot.
Every shipment includes the printed COA for the specific lot you receive. You can view the current batch COA via the link on this page.
For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or dietary supplement. Retatrutide is an investigational compound not approved by the FDA or any other regulatory agency.
Lyophilized (as shipped):
- Stable at room temperature for short periods during transit.
- For long-term storage, keep desiccated at –20°C or below. Shelf life: 24 months from date of synthesis when stored as directed.
Reconstituted:
- After reconstitution in bacteriostatic water or sterile water, store at 2–8°C (refrigerated) and use within 2–7 days.
- For longer storage after reconstitution, aliquot and freeze below –18°C. Avoid repeated freeze-thaw cycles.
- The C20 fatty diacid side chain confers albumin-binding behavior and contributes to the peptide's extended circulation half-life in published pharmacokinetic studies. The modification also affects solubility characteristics — reconstitute slowly and allow adequate dissolution time.
Physical characteristics:
- Lyophilized form: white powder.
- Soluble in bacteriostatic and sterile water. May require gentle agitation.
For research use only. Storage guidance is derived from published peptide chemistry literature and is provided for laboratory handling purposes.
- Transit time: 2–4 business days with tracked delivery.
- Cold-pack insert: Every order ships with a cold-pack insert to buffer against temperature excursions during transit. Lyophilized peptides are stable at ambient temperature for short periods; the cold pack is an additional margin of safety.
- Tracking: Tracking number provided at dispatch.
- Duties and taxes: Included in the listed price for standard destinations.
- Replacement coverage: If your order arrives damaged, delayed beyond the stated window, or with compromised packaging, contact us within 7 days of delivery for a replacement at no cost.
- Shipping restrictions: We do not ship to jurisdictions where the sale of research peptides is restricted. If you are uncertain whether your jurisdiction permits import, consult local regulations before ordering.
Is this product for human use?
No. Retatrutide is sold strictly for in-vitro and preclinical research use. It is an investigational compound currently in Phase 3 clinical trials conducted by Eli Lilly and Company. It is not approved by the FDA or any other regulatory agency for human or veterinary use outside of those sanctioned trials. It is not a drug, food, cosmetic, or dietary supplement. Purchase indicates agreement that the material will be used solely for laboratory research by qualified personnel.
What is Retatrutide's development status?
Retatrutide (development code LY3437943) was originated by Eli Lilly and Company. As of 2026, it is undergoing Phase 3 clinical trials through Lilly's TRIUMPH program. The compound has not received marketing approval from any regulatory agency. The material offered here is a research-grade synthetic reproduction of the published peptide structure, intended for independent laboratory research — not a pharmaceutical preparation.
How is the sequence verified?
Retatrutide contains three non-coded residues (2-aminoisobutyric acid at positions 2 and 20, α-methyl-leucine at position 13) and a C20 fatty diacid side chain conjugated at Lys20. Mass spectrometry confirms the full molecular weight against the expected 4731.33 Da. The modifications and sequence are verified against the peer-reviewed published structure during Fmoc solid-phase synthesis.
Why is Retatrutide more expensive than shorter peptides?
Retatrutide's 39-amino-acid length and multiple non-natural amino acid modifications require significantly more synthesis steps and specialized reagents than shorter peptides like BPC-157 or GHK-Cu. The C20 fatty diacid conjugation adds additional chemistry steps. Per-milligram cost reflects the synthetic complexity, not a markup.
How do I access the Certificate of Analysis?
Each order ships with a printed COA for the exact lot you receive. You can also view the current batch COA as a PDF via the link on this page before ordering. COAs include HPLC purity, mass spectrometry confirmation of the modified sequence, water content, and endotoxin testing results.
What are the shipping restrictions?
We ship to jurisdictions where the sale of research peptides is permitted. We do not ship to regions where possession or import of these compounds is restricted. Because Retatrutide is an investigational compound under active development, some jurisdictions may have additional restrictions — please consult your local regulations before ordering.